Sodium glucose co-transporter 2 inhibitors in heart failure therapy
Göster/ Aç
Tarih
2020Yazar
Cavusoglu, Yuksel
Altay, Hakan
Cahn, Avivit
Celik, Ahmet
Demir, Serafettin
Kilicaslan, Baris
Nalbantgil, Sanem
Raz, Itamar
Temizhan, Ahmet
Yildirimturk, Ozlem
Yilmaz, Mehmet Birhan
Üst veri
Tüm öğe kaydını gösterÖzet
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis. In large, randomized clinical trials, SGLT-2i have been shown to reduce major cardiovascular (CV) events and heart failure (HF) hospitalizations in patients with T2DM who have atherosclerotic CV disease or CV risk factors. In these trials, SGLT-2i is have their greatest and most consistent effect on reducing the risk of HF hospitalization. The reduction in HF hospitalization was also observed in subgroups of patients with a HF diagnosis at baseline, which raised the possibility of a clinical benefit of SGLT-2i in HF patients, regardless of the presence or absence of T2DM. In very recently published DAPA-HF trial, a SGLT-2i, dapagliflozin treatment on top of standard HF therapy has been shown to have clear clinical benefits in terms of reducing HF hospitalization, CV mortality, all-cause mortality and improving quality of life in HF patients. This compelling evidence suggests that SGLT-2i have a potential to be an effective treatment option in HF, regardless of diabetes. This article provides a comprehensive overview focused on the role of SGLT-2i in the treatment of HF.
Koleksiyonlar
- PubMed Açık Erişimli Yayınlar [1472]
- PubMed İndeksli Yayınlar Koleksiyonu [2382]
- Scopus Açık Erişimli Yayınlar [532]
- Scopus İndeksli Yayınlar Koleksiyonu [3057]
- Tıp Fakültesi / Faculty of Medicine [5916]
- TR-Dizin Açık Erişimli Yayınlar [896]
- TR-Dizin İndeksli Yayınlar Koleksiyonu [984]
- Wos Açık Erişimli Yayınlar [2402]
- Wos İndeksli Yayınlar Koleksiyonu [4123]